US FDA allows device firms to self-identify and correct problems in place of inspections
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is working on a pilot program that will allow medical device companies to self-identify and correct possible regulatory violations in place of undergoing FDA inspections1.